Author

Colleen W. Marano 1

1 Janssen Research & Development, LLC,Spring House,United States

AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY

Walter Reinisch, Colleen W. Marano, Allison Simi, John Lynch, Lenore Noonan, Hongyan Zhang, Bruce E. Sands, Daniel S. Mishkin

CORTICOSTEROID-SPARING EFFECTS OF USTEKINUMAB THERAPY FOR ULCERATIVE COLITIS THROUGH 4 YEARS: UNIFI LONG-TERM EXTENSION

Ramesh P. Arasaradnam, Ellen J. Scherl, David Rowbotham, Silvio Danese, William J. Sandborn, Ye Miao, Hongyan Zhang, Remo Panaccione, Waqqas Afif, Tadakazu Hisamatsu, Rupert W Leong, Bruce E. Sands, Maria T. Abreu, Colleen W. Marano

EARLY AND SUSTAINED REMISSION AFTER TREATMENT WITH SC ADMINISTERED GOLIMUMAB IS ASSOCIATED WITH NORMALIZED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: POSTHOC-ANALYSIS FROM PURSUIT INDUCTION AND MAIN

Walter Reinisch, Brian G. Feagan, Colleen W. Marano, Richard S Strauss, C. Han, T Gathany, Jewel Johanns, Hongjie Zhang, Peter R. Gibson, John Collins, Paul Rutgeerts, Jean-Frederic Colombel, Brian G. Feagan, Gunnar Jarnerot, William Sandborn

EARLY DOSE OPTIMIZATION IN NONRESPONDERS TO GOLIMUMAB INDUCTION TREATMENT FOR ULCERATIVE COLITIS IS SUPPORTED BY PHARMACOKINETIC DATA THROUGH 1 YEAR

George Philip, Colleen W. Marano, Omoniyi J. Adedokun, Richard Melsheimer, Freddy Cornillie

EARLY RESPONSES IN PATIENT-REPORTED OUTCOMES ARE PREDICTORS FOR MUCOSAL HEALING IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH GOLIMUMAB- RESULTS FROM PURSUIT SC INDUCTION

Walter Reinisch, Brian G. Feagan, Colleen W. Marano, Richard S Strauss, C. Han, Jewel Johanns, Hongjie Zhang, Peter R. Gibson, John Collins, Paul Rutgeerts, William Sandborn, Jean-Frederic Colombel, Brian G. Feagan, Gunnar Jarnerot

EFFECT OF USTEKINUMAB MAINTENANCE THERAPY ON STOOL FREQUENCY AND RECTAL BLEEDING THROUGH 2 YEARS IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS

Laurent Peyrin-Biroulet, Maria T. Abreu, Silvio Danese, Colleen W. Marano, Yiying Zhou, Hongyan Zhang, Rupert W Leong, David Rowbotham, Remo Panaccione, William Sandborn

EFFECTS OF IMMUNOMODULATORS ON THE PHARMACOKINETICS AND EFFICACY OF GOLIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM PHASE 2/3 PURSUIT –SC INDUCTION AND MAINTENANCE STUDIES

Zhi-jie Xu, Colleen W. Marano, Richard S Strauss, Hongjie Zhang, H M Davis, Walter Reinisch, Brian G. Feagan, Paul Rutgeerts, Omoniyi J. Adedokun, Jean-Frederic Colombel, William Sandborn

EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS

Silvio Danese, Ana Caroline Costa Sa, Colleen W. Marano, Bruce E. Sands, Laurent Peyrin-Biroulet

Effects of Ustekinumab Maintenance Therapy on Endoscopic Improvement and Histologic Improvement in the UNIFI Phase 3 Study in Ulcerative Colitis

Katherine Li, Joshua R. Friedman, Colleen W. Marano, Hongyan Zhang, Feifei Yang, William Sandborn, Bruce E. Sands, Brian G. Feagan, Laurent Peyrin-Biroulet, Gert De Hertogh

Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 2 Years: UNIFI Long-term Extension

Bruce E. Sands, William Sandborn, Remo Panaccione, Christopher D. O'Brien, Hongyan Zhang, Jewel Johanns, Yiying Zhou, Ilia Tikhonov, Laurent Peyrin-Biroulet, Gert Van Assche, Silvio Danese, Stephan Targan, Maria T. Abreu, Tadakazu Hisamatsu, Ellen Scherl, Rupert W Leong, David Rowbotham, Ramesh P. Arasaradnam, Colleen W.

Item 1 - 10 / 37
1
2 3 4